Our research is dedicated to the translation of basic science to the clinic, always focusing on the patient who should benefit from our research results in the near future.

Acute lymphocytic leukemia (ALL) is the second most common leukemia mainly occurring in two patient populations, a) in children under the age of 5 years and b) in adults over the age of 50 years. Although the traditional multiagent chemotherapy regimens induce high complete remission (CR) rates, many adult patients experience relapse of their disease. Despite the breakthrough advances of antibody-based therapies, the overall long-term survival rate for patients with relapsed or refractory ALL, as well as for certain genetic subtypes is still dismal emphasizing the need for novel, targeted treatment strategies.

By applying a multi-omics approach, as well as innovative screening strategies and complementing our results with clinical patient samples and data, our goal is to identify new oncogenic transcriptional networks in acute lymphoblastic leukemia (ALL) which will ultimately lead to new targeted treatment strategies for patients with this disease